PDL BioPharma Announces Settlement Agreement with Valeant
About
PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, PDL has consummated 17 such transactions, of which nine are active and outstanding. PDL has one debt transaction outstanding, representing deployed and committed capital of
NOTE: PDL,
View original content with multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-announces-settlement-agreement-with-valeant-300545275.html
SOURCE
News Provided by Acquire Media